Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AGIO 
Agios Pharm (AGIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: AGIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $51.71
1 Year Target Price $51.71
| 3 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.6% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.26B USD | Price to earnings Ratio 3.38 | 1Y Target Price 51.71 |
Price to earnings Ratio 3.38 | 1Y Target Price 51.71 | ||
Volume (30-day avg) 9 | Beta 0.73 | 52 Weeks Range 23.41 - 62.58 | Updated Date 07/12/2025 |
52 Weeks Range 23.41 - 62.58 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1798.26% | Operating Margin (TTM) -1221.97% |
Management Effectiveness
Return on Assets (TTM) -22.88% | Return on Equity (TTM) 60.26% |
Valuation
Trailing PE 3.38 | Forward PE 2.47 | Enterprise Value 1421153520 | Price to Sales(TTM) 61.07 |
Enterprise Value 1421153520 | Price to Sales(TTM) 61.07 | ||
Enterprise Value to Revenue 38.37 | Enterprise Value to EBITDA -2.33 | Shares Outstanding 57915200 | Shares Floating 51249739 |
Shares Outstanding 57915200 | Shares Floating 51249739 | ||
Percent Insiders 1.65 | Percent Institutions 101.39 |
Upturn AI SWOT
Agios Pharm
Company Overview
History and Background
Agios Pharmaceuticals, founded in 2008, is a biopharmaceutical company focused on discovering and developing novel therapeutics targeting cellular metabolism to treat cancer and rare genetic diseases. Initially focused on cancer metabolism, Agios has expanded its focus to genetic diseases. They achieved significant milestones with the FDA approval of several drugs developed in-house.
Core Business Areas
- Oncology: Focuses on developing therapies for various cancers by targeting specific metabolic pathways. Currently not a large part of Agios as of 2021 due to divesting their oncology business.
- Rare Genetic Diseases: Focuses on developing therapies for rare anemias and other genetic diseases. The lead drug in this segment is Pyrukynd (mitapivat).
Leadership and Structure
Agios is led by CEO Brian Goff. The organizational structure includes departments for Research and Development, Commercial Operations, Medical Affairs, and Corporate Affairs.
Top Products and Market Share
Key Offerings
- Pyrukynd (mitapivat): Pyrukynd is an oral PK activator indicated for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Competitors include supportive care treatments like blood transfusions. Market share is evolving as Pyrukynd is a relatively new drug, with revenue growing over time. No specific market share data available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, regulatory hurdles, and significant investment requirements. It is highly competitive, with a mix of large pharmaceutical companies and smaller biotech firms. The focus on rare diseases is growing due to incentives and unmet medical needs.
Positioning
Agios positions itself as a leader in targeting cellular metabolism for therapeutic intervention. Its competitive advantage lies in its proprietary platform and expertise in this area, focusing on rare genetic diseases where unmet needs are high.
Total Addressable Market (TAM)
The global pyruvate kinase deficiency market is estimated at hundreds of millions of dollars and Agios Pharm aims to secure a substantial portion of it. The exact TAM is constantly evolving as new therapies emerge.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting cellular metabolism
- FDA-approved products
- Strong research and development capabilities
- Focus on rare diseases with unmet medical needs
Weaknesses
- Reliance on a limited number of products
- High research and development expenses
- Commercialization risks
- Potential competition from larger pharmaceutical companies
Opportunities
- Expansion into new disease areas
- Partnerships and collaborations
- Regulatory incentives for rare disease treatments
- Increasing awareness of cellular metabolism in disease
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing and emerging therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- SNY
- NVO
- MRK
- LLY
Competitive Landscape
Agios faces competition from large pharmaceutical companies and other biotech firms, each with their own strengths and weaknesses. Agios distinguishes itself by focusing on cellular metabolism. The company's selling off of its oncology business means it plays a much smaller part of the overall market share in those areas.
Growth Trajectory and Initiatives
Historical Growth: Agios's growth has been driven by the development and commercialization of novel therapies.
Future Projections: Future growth depends on the success of its pipeline products, particularly Pyrukynd, and its ability to expand into new therapeutic areas.
Recent Initiatives: Focus on rare genetic diseases, commercialization of Pyrukynd, continued investment in research and development.
Summary
Agios Pharmaceuticals is a biopharmaceutical company with a focus on rare genetic diseases. Its strength lies in its novel approach to targeting cellular metabolism and in its FDA-approved product, Pyrukynd. However, its reliance on a limited product portfolio and the competitive landscape present challenges. Future success depends on the commercial success of Pyrukynd and expanding its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agios Pharm
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2013-07-24 | CEO & Director Mr. Brian M. Goff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 486 | Website https://www.agios.com |
Full time employees 486 | Website https://www.agios.com | ||
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.